The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Abstract
The hCHK2 gene encodes the human homolog of the yeast Cds1 and Rad53 G 2 checkpoint kinases, whose activation in response to DNA damage prevents cellular entry into mitosis. Here, it is shown that heterozygous germ line mutations in hCHK2 occur in Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in the TP53 gene. These observations suggest that hCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and they also provide a link between the central role of p53 inactivation in human cancer and the well-defined G 2 checkpoint in yeast.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Self-citationCheckpoints: Controls That Ensure the Order of Cell Cycle Events
Hartwell, L. H., & Weinert, T. A. (1989) · Science · doi:10.1126/science.2683079 · Cited by 3,021
Universal control mechanism regulating onset of M-phase
Nurse, P. (1990) · Nature · doi:10.1038/344503a0 · Cited by 2,831
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Self-citationMutations of mitotic checkpoint genes in human cancers
Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/32688 · Cited by 1,486
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Cited by
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
The DNA damage response: putting checkpoints in perspective
Zhou, B.-B. S., & Elledge, S. J. (2000) · Nature · doi:10.1038/35044005 · Cited by 3,213
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577
“Noteworthy, the CHEK2 gene that encodes this protein was suggested to act as a tumour suppressor in subsets of patients with the cancer-predisposing Li–Fraumeni syndrom”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Cell cycle checkpoint signaling through the ATM and ATR kinases
Abraham, R. T. (2001) · Genes & Development · doi:10.1101/gad.914401 · Cited by 1,966
An Oncogene-Induced DNA Damage Model for Cancer Development
Halazonetis, T. D., Gorgoulis, V. G., & Bartek, J. (2008) · Science · doi:10.1126/science.1140735 · Cited by 1,851
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
DNA Damage-Induced Activation of p53 by the Checkpoint Kinase Chk2
Hirao, A., Kong, Y.-Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., & Mak, T. W. (2000) · Science · doi:10.1126/science.287.5459.1824 · Cited by 1,285
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Cell death by mitotic catastrophe: a molecular definition
Castedo, M., Perfettini, J.-L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207528 · Cited by 1,269
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Protein–protein interactions define specificity in signal transduction
Pawson, T., & Nash, P. (2000) · Genes & Development · doi:10.1101/gad.14.9.1027 · Cited by 780
Toward Maintaining the Genome: DNA Damage and Replication Checkpoints
Nyberg, K. A., Michelson, R. J., Putnam, C. W., & Weinert, T. A. (2002) · Annual Review of Genetics · doi:10.1146/annurev.genet.36.060402.113540 · Cited by 777
Yoshida, K., & Miki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02195.x · Cited by 753
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Self-citationInterfaces Between the Detection, Signaling, and Repair of DNA Damage
Rouse, J., & Jackson, S. P. (2002) · Science · doi:10.1126/science.1074740 · Cited by 694
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Cellular Responses to DNA Damage
Norbury, C. J., & Hickson, I. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.367 · Cited by 623
Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer
Pharoah, P. D. P., Antoniou, A. C., Easton, D. F., & Ponder, B. A. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0708739 · Cited by 618
Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations
Gonzalez, K. D., Noltner, K. A., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Nguyen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6959 · Cited by 609
Mammalian G1- and S-phase checkpoints in response to DNA damage
Bartek, J., & Lukas, J. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00280-5 · Cited by 573
CHEK2 Is a Multiorgan Cancer Susceptibility Gene
Cybulski, C., Górski, B., Huzarski, T., Masojć, B., Mierzejewski, M., Dębniak, T., Teodorczyk, U., Byrski, T., Gronwald, J., Matyjasik, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/426403 · Cited by 551
Bernstein, C. (2002) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(02)00009-1 · Cited by 527
“However, some cases of Li–Fraumini do not exhibit a p53 genetic defect, but instead exhibit heterozygous germ line mutations in thehCHK2 gene[258].”
BackgroundMrc1 transduces signals of DNA replication stress to activate Rad53
Alcasabas, A. A., Osborn, A. J., Bachant, J., Hu, F., Werler, P. J. H., Bousset, K., Furuya, K., Diffley, J. F. X., Carr, A. M., & Elledge, S. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-958 · Cited by 524
DNA Methyltransferases, DNA Damage Repair, and Cancer
Jin, B., & Robertson, K. D. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-9967-2_1 · Cited by 519
Malkin, D. (2011) · Genes & Cancer · doi:10.1177/1947601911413466 · Cited by 508
UK guidelines for the management of soft tissue sarcomas
Dangoor, A., Seddon, B., Gerrand, C., Grimer, R., Whelan, J., & Judson, I. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0060-4 · Cited by 477
Pathways governing G1/S transition and their response to DNA damage
Bartek, J., & Lukas, J. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02114-7 · Cited by 471
(2004) · The American Journal of Human Genetics · doi:10.1086/421251 · Cited by 471
Maintenance of Genome Stability in Saccharomyces cerevisiae
Kolodner, R. D., Putnam, C. D., & Myung, K. (2002) · Science · doi:10.1126/science.1075277 · Cited by 468
A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer
Vahteristo, P., Bartkova, J., Eerola, H., Syrjäkoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomäki, K., Heikkilä, P., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341943 · Cited by 467
Chromosome segregation and cancer: cutting through the mystery
Jallepalli, P. V., & Lengauer, C. (2001) · Nature Reviews Cancer · doi:10.1038/35101065 · Cited by 463
Durocher, D., Taylor, I. A., Sarbassova, D., Haire, L. F., Westcott, S. L., Jackson, S. P., Smerdon, S. J., & Yaffe, M. B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00114-3 · Cited by 456
Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
Busino, L., Donzelli, M., Chiesa, M., Guardavaccaro, D., Ganoth, D., Valerio Dorrello, N., Hershko, A., Pagano, M., & Draetta, G. F. (2003) · Nature · doi:10.1038/nature02082 · Cited by 447
Regulating mammalian checkpoints through Cdc25 inactivation
Donzelli, M., & Draetta, G. F. (2003) · EMBO reports · doi:10.1038/sj.embor.embor887 · Cited by 438
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
DNA damage checkpoints in mammals
Niida, H., & Nakanishi, M. (2006) · Mutagenesis · doi:10.1093/mutage/gei063 · Cited by 432
Guidelines for the Management of Soft Tissue Sarcomas
Grimer, R., Judson, I., Peake, D., & Seddon, B. (2010) · Sarcoma · doi:10.1155/2010/506182 · Cited by 432
GermlineTP53 mutations and Li-Fraumeni syndrome
Varley, J. M. (2003) · Human Mutation · doi:10.1002/humu.10185 · Cited by 430
Self-citationDurocher, D., & Jackson, S. P. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03294-x · Cited by 428
DiTullio, R. A., Mochan, T. A., Venere, M., Bartkova, J., Sehested, M., Bartek, J., & Halazonetis, T. D. (2002) · Nature Cell Biology · doi:10.1038/ncb892 · Cited by 407
Hirao, A., Cheung, A., Duncan, G., Girard, P.-M., Elia, A. J., Wakeham, A., Okada, H., Sarkissian, T., Wong, J. A., Sakai, T., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.18.6521-6532.2002 · Cited by 404
Chk2 kinase — a busy messenger
Bartek, J., Falck, J., & Lukas, J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35103059 · Cited by 403
The p53 pathway in breast cancer
Gasco, M., Shami, S., & Crook, T. (2002) · Breast Cancer Research · doi:10.1186/bcr426 · Cited by 393
Cell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388
Chk2 activates E2F-1 in response to DNA damage
Stevens, C., Smith, L., & La Thangue, N. B. (2003) · Nature Cell Biology · doi:10.1038/ncb974 · Cited by 385
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
The evolution of diverse biological responses to DNA damage: insights from yeast and p53
Wahl, G. M., & Carr, A. M. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-e277 · Cited by 376
Phosphoserine/threonine-binding domains
Yaffe, M. B., & Elia, A. E. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00189-7 · Cited by 354
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336
Lack of PTEN sequesters CHK1 and initiates genetic instability
Puc, J., Keniry, M., Li, H. S., Pandita, T. K., Choudhury, A. D., Memeo, L., Mansukhani, M., Murty, V. V. V. S., Gaciong, Z., Meek, S. E. M., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.009 · Cited by 328
Myung, K., Datta, A., & Kolodner, R. D. (2001) · Cell · doi:10.1016/s0092-8674(01)00227-6 · Cited by 327
Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair
Zhang, J., Willers, H., Feng, Z., Ghosh, J. C., Kim, S., Weaver, D. T., Chung, J. H., Powell, S. N., & Xia, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.708-718.2004 · Cited by 323
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes
Greenberg, R. A., Sobhian, B., Pathania, S., Cantor, S. B., Nakatani, Y., & Livingston, D. M. (2006) · Genes & Development · doi:10.1101/gad.1381306 · Cited by 308
Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1
Melchionna, R., Chen, X.-B., Blasina, A., & McGowan, C. H. (2000) · Nature Cell Biology · doi:10.1038/35036406 · Cited by 311
Mutations in CHEK2 Associated with Prostate Cancer Risk
Dong, X., Wang, L., Taniguchi, K., Wang, X., Cunningham, J. M., McDonnell, S. K., Qian, C., Marks, A. F., Slager, S. L., Peterson, B. J., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/346094 · Cited by 308
Weischer, M., Bojesen, S. E., Ellervik, C., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5922 · Cited by 306
Genetic Predisposition to Breast Cancer: Past, Present, and Future
Turnbull, C., & Rahman, N. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164339 · Cited by 302
A DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1
Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., & Lu, H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00176-9 · Cited by 299
Damage Tolerance Protein Mus81 Associates with the FHA1 Domain of Checkpoint Kinase Cds1
Boddy, M. N., Lopez-Girona, A., Shanahan, P., Interthal, H., Heyer, W.-D., & Russell, P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8758-8766.2000 · Cited by 290
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
To die or not to die: how does p53 decide?
Slee, E. A., O'Connor, D. J., & Lu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 278
Molecular Pathogenesis of Osteosarcoma
Kansara, M., & Thomas, D. M. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0505 · Cited by 273
Adrenocortical cancer: pathophysiology and clinical management
Libè, R., Fratticci, A., & Bertherat, J. (2007) · Endocrine-Related Cancer · doi:10.1677/erc.1.01130 · Cited by 272
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267
Ye, X., Franco, A. A., Santos, H., Nelson, D. M., Kaufman, P. D., & Adams, P. D. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00037-6 · Cited by 267
Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage
Berman, S. D., Calo, E., Landman, A. S., Danielian, P. S., Miller, E. S., West, J. C., Fonhoue, B. D., Caron, A., Bronson, R., Bouxsein, M. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805462105 · Cited by 266
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
The Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 257
ATM, a central controller of cellular responses to DNA damage
Khanna, K., Lavin, M., Jackson, S., & Mulhern, T. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400874 · Cited by 252
14-3-3 Proteins—a focus on cancer and human disease
Wilker, E., & Yaffe, M. B. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.04.015 · Cited by 252
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Friedreich ataxia: the oxidative stress paradox
Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.-C., Koenig, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi042 · Cited by 219
Chk2 Activation Dependence on Nbs1 after DNA Damage
Buscemi, G., Savio, C., Zannini, L., Miccichè, F., Masnada, D., Nakanishi, M., Tauchi, H., Komatsu, K., Mizutani, S., Khanna, K., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.15.5214-5222.2001 · Cited by 201
DNA damage checkpoint kinase Chk2 triggers replicative senescence
Gire, V., Roux, P., Wynford‐Thomas, D., Brondello, J., & Dulic, V. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600259 · Cited by 198
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Libé, R., & Bertherat, J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02004 · Cited by 168
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124
“LFS is normally associated with germline mutations in p53; however, the patients with Chk2 mutation had wild-type germline p53 (Bell et al, 1999).”
BackgroundQuestioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage Response
Ahn, J., Urist, M., & Prives, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213185200 · Cited by 99
Kerzendorfer, C., & O’Driscoll, M. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.04.018 · Cited by 97
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
Concomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91
“Heterozygous germ-line mutations in Chk2 were reported in individuals with the cancer predisposition Li-Fraumeni syndrome who lacked p53 mutations (Bell et al., 1999), implying that loss of function in Chk2 might be functionally equivalent to p53 mutation.”
BackgroundInfluentialMutation analysis of the CHK2gene in families with hereditary breast cancer
Allinen, M., Huusko, P., Mäntyniemi, S., Launonen, V, & Winqvist, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1858 · Cited by 85
Mutation analysis of the CHK2 gene in breast carcinoma and other cancers
Ingvarsson, S., Sigbjornsdottir, B. I., Huiping, C., Hafsteinsdottir, S. H., Ragnarsson, G., Barkardottir, R. B., Arason, A., Egilsson, V., & Bergthorsson, J. T. (2002) · Breast Cancer Research · doi:10.1186/bcr435 · Cited by 63
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Metadata
- Authors
- Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., Birch, J. M., Li, F. P., Garber, J. E., & Haber, D. A.
- Venue
- Science
- Published
- 1999-12-24
- Volume
- 286
- Issue
- 5449
- Pages
- 2528-2531
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2166548889
- Cited by
- 904
- References
- 54
- FWCI
- 26.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.